Multiple biomarker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: A cross-sectional study

Population Health Metrics

Volumn 13, Issue 1, 2015, Pages

  Coffman, Evan ^a   Richmond Bryant, Jennifer ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Biomarkers; Cardiovascular disease; Joint associations; Metabolic syndrome; NHANES

Indexed keywords

APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACCURACY ASSESSMENT; BIOMARKER; CARDIOVASCULAR DISEASE; DISEASE INCIDENCE; HEALTH RISK; METABOLISM; MULTIVARIATE ANALYSIS; PROTEIN;

ADULT; ANGINA PECTORIS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CROSS-SECTIONAL STUDY; FASTING GLUCOSE; FEMALE; HEART INFARCTION; HUMAN; INCOME TO POVERTY RATIO; ISCHEMIC HEART DISEASE; JOINT ASSOCIATION MODEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; SOCIOECONOMICS; STATISTICAL MODEL;

EID: 84924905667     PISSN: None     EISSN: 14787954     Source Type: Journal    
DOI: 10.1186/s12963-015-0041-5     Document Type: Article

References (48)

1. Beltran-Sanchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population. J Am Coll Cardiol 2013. 1999;62(8):697-703.
2. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112(20):3066-72.
3. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. Definition of metabolic syndrome: report of the national heart, lung, and blood institute/american heart association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004;24(2):e13-18.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA. 2002;287(3):356-9.
5. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159(10):1104-9.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-43.
7. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol. 2002;39(9):1414-21.
8. Koenig W. Cardiovascular biomarkers: added value with an integrated approach? Circulation. 2007;116(1):3-5.
9. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47.
10. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003.
11. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105(3):310-5.
12. NHANES 1999-2000 [ http://wwwn.cdc.gov/nchs/nhanes/search/nhanes99_00.aspx ]
13. NHANES 2001-2002 [ http://wwwn.cdc.gov/nchs/nhanes/search/nhanes01_02.aspx ]
14. NHANES 2003-2004 [ http://wwwn.cdc.gov/nchs/nhanes/search/nhanes03_04.aspx ]
15. NHANES 2005-2006 [ http://wwwn.cdc.gov/nchs/nhanes/search/nhanes05_06.aspx ]
16. NHANES 2007-2008 [ http://wwwn.cdc.gov/nchs/nhanes/search/nhanes07_08.aspx ]
17. NHANES 2009-2010 [ http://wwwn.cdc.gov/nchs/nhanes/search/nhanes09_10.aspx ]
18. Curtin LR, Mohadjer LK, Dohrmann SM, Montaquila JM, Kruszan-Moran D, Mirel LB, et al. The National Health and Nutrition Examination Survey: Sample Design, 2007-2010. Vital and health statistics Series 2, Data evaluation and methods research. 2013(160):1-32
19. Curtin LR, Mohadjer LK, Dohrmann SM, Montaquila JM, Kruszan-Moran D, Mirel LB, et al. The National Health and Nutrition Examination Survey: Sample Design, 1999-2006. Vital and health statistics Series 2, Data evaluation and methods research 2012(155):1-39.
20. 1999-2000 Lab Methods [ http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/lab_methods_99_00.htm ]
21. 2001-2002 Lab Methods [ http://www.cdc.gov/nchs/nhanes/nhanes2001-2002/lab_methods_01_02.htm ]
22. 2003-2004 Lab Methods [ http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/lab_methods_03_04.htm ]
23. 2005-2006 Lab Methods [ http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/lab_methods_05_06.htm ]
24. 2007-2008 Lab Methods [ http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/lab_methods_07_08.htm ]
25. 2009-2010 Lab Methods [ http://www.cdc.gov/nchs/nhanes/nhanes2009-2010/lab_methods_09_10.htm ]
26. Johnson CL, Paulose-Ram R, Ogden CL, Carroll MD, Kruszan-Moran D, Dohrmann SM, et al. National health and nutrition examination survey: analytic guidelines, 1999-2010. Vital Health Stat 2 Data evaluation and methods research. 2013;161:1-24.
27. Winquist A, Kirraine E, Klein M, Strickland M, Darrow L, Sarnat S, et al. Joint effects of ambient air pollutants on pediatric asthma emergency department visits in Atlanta, 1998-2004. Epidemiology 2014.
28. Levy JI. Is epidemiology the key to cumulative risk assessment? Risk Anal. 2008;28(6):1507-13.
29. Kleinbaum D, Klein M. Logistic regression - a self learning text. In. Gail M, Krickeberg K, Samet J, Tsiatis A, Wong W, editors. Third edn. New York: Springer; 2010
30. Heeringa S, Brady WT, Berglund PA. Applied Survey Data Analysis. Boca Raton: Taylor & Francis; 2010.
31. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: John Wiley & Sons; 2000.
32. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
33. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363-9.
34. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391-7.
35. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol. 2002;55(5):445-51.
36. Myint PK, Sinha S, Wareham NJ, Bingham SA, Luben RN, Welch AA, et al. Glycated hemoglobin and risk of stroke in people without known diabetes in the european prospective investigation into cancer (EPIC)-Norfolk prospective population study: a threshold relationship? Stroke. 2007;38(2):271-5.
37. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450-8.
38. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23(12):1835-9.
39. Ford ES, Ajani UA, Mokdad AH. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care. 2005;28(4):878-81.
40. Sarwar N, Sattar N. Triglycerides and coronary heart disease: have recent insights yielded conclusive answers? Curr Opin Lipidol. 2009;20(4):275-81.
41. Resnick HE, Howard BV. Diabetes and cardiovascular disease. Annu Rev Med. 2002;53:245-67.
42. Wingard DL, Barrett-Connor E. Heart Disease and Diabetes. In: Diabetes in America. 2nd edn. Washington DC: US Government Printing Offices; 1995.
43. Pearce N, Checkoway H, Kriebel D. Bias in occupational epidemiology studies. Occup Environ Med. 2007;64(8):562-8.
44. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke. 1999;30(5):981-5.
45. Goldstein LB, Amarenco P, Zivin J, Messig M, Altafullah I, Callahan A, et al. Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke. 2009;40(11):3526-31.
46. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ (Clinical research ed). 1997;314(7090):1303-6.
47. Wong ND, Wilson PW, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med. 1991;115(9):687-93.
48. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24months of follow-up in patients under thrombolytic treatment. Eur Heart J. 1996;17(9):1345-9.